Has Taxiarchis Kourelis, MD received payments from drug or device companies?

Yes. Drug and device makers reported $3,699 in general payments to Taxiarchis Kourelis, MD across 4 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Taxiarchis Kourelis, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Taxiarchis Kourelis, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Taxiarchis Kourelis, MD

Hematology · Rochester, MNNPI 1710116967

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $3,572 of the $3,699 with a category attached, or 96.6%. E.r. Squibb & Sons, L.L.C. accounts for 65.5% of it on its own, with 3 other manufacturers making up the rest.

$3,699in general payments, 2019–2025

Across 4 payments — averaging $924.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

E.r. Squibb & Sons, L.L.C.$2K
Janssen Scientific Affairs, LLC$1K
Karyopharm Therapeutics Inc.$110
Sanofi$18

$229,499in research payments, 2019–2025

Across 5 payments — averaging $45,900 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Bristol Myers Squibb$120K
Pfizer$75K
Janssen Research & Development, LLC$35K

What the payments were for

Consulting fees$3,57297%
Food & beverage$1273%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
E.r. Squibb & Sons, L.L.C.	1	$2,422
Janssen Scientific Affairs, LLC	1	$1,150
Karyopharm Therapeutics Inc.	1	$110
Sanofi	1	$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

TECVAYLI$1,150
XPOVIO$110

How this compares

$3,699 in reported general payments places this provider in the 65th percentile of 111 hematology providers in Minnesota.

See all hematology providers in Minnesota →

Medicare billing

Part B allowed, 2024

$377,990

Medicare patients

268

Services billed

25,154

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
RevlimidLenalidomide	56	$1,018,629
PomalystPomalidomide	18	$365,571
KineretAnakinra	11	$60,049
Acyclovir	72	$1,025
Dexamethasone	23	$302
Gabapentin	12	$207
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim	14	$93

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
E.r. Squibb & Sons, L.L.C.Pomalyst	$2,422	$365,57118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 111 hematology providers in Minnesota.

Other hematology in Rochester

Shaji KumarRochester$452K
Yi LinRochester$365K
David DingliRochester$299K
Morie GertzRochester$261K
Grzegorz NowakowskiRochester$235K
Sameer ParikhRochester$151K
Lindsey RoekerRochester$106K
Mark LitzowRochester$99K
Angela DispenzieriRochester$87K
Prashant KapoorRochester$71K

See the full list for Minnesota →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →